[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atheroscleroses-coronary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atheroscleroses-coronary":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,56,82,105,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100637404","ai-assisted-ct-for-risk-stratification-in-coronary-artery-disease-action-100637404",false,"NCT07577609","AI-assisted CT for Risk Stratification in Coronary Artery Disease (ACTION)","Artificial Intelligence-assisted CT for Risk Stratification in COronary Artery Disease to PreveNt Future Coronary Events and Improve Outcomes","ACTION","Inclusion Criteria:\n\n* Adults aged ≥18 years\n* Undergoing clinically indicated cardiac CT\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* History of malignancy\n* Abnormal renal function (e.g., eGFR or serum creatinine outside reference range)\n* Contraindications to iodinated contrast agents or CT imaging",true,"ALL","18 Years",{"count":21,"type":22},10000,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT.\n\nThe main questions it aims to answer are:\n\n* Can AI-enhanced cardiac CT accurately assess cardiovascular risk in a real-world adult population?\n* How do CT-derived plaque characteristics correlate with clinical, biochemical, and lifestyle risk factors? Researchers will compare subgroups (e.g., patients with different risk profiles, biomarkers, or imaging findings, and a subset undergoing OCT imaging) to see if differences in imaging and clinical parameters are associated with cardiovascular risk and plaque vulnerability.\n\nParticipants will:\n\n* Provide informed consent and medical history\u002Fdemographic information\n* Undergo blood sampling for cardiovascular and metabolic biomarkers\n* Have a resting ECG performed\n* Complete a detailed lifestyle and health questionnaire\n* Receive a non-invasive cardiac CT scan interpreted by an expert\n* Potentially receive heart rate-lowering medication (e.g., metoprolol) if required for imaging quality\n* Be referred for further clinical evaluation if clinically indicated ",[27,28,29,30,31,32,33],"Coronary Artery Disease (CAD)","Computed Tomography Angiography","Biomarkers","AI (Artificial Intelligence)","Lipoprotein(a)","Atheroscleroses, Coronary","Myocardial Ischemia",[35,36,37,38,39,40,41,42],"AI-assisted cardiac CT","Coronary CT angiography (CCTA)","Cardiovascular risk stratification","Coronary plaque characterization","High-risk plaque","Machine learning","CT-FFR (fractional flow reserve)","Coronary calcium scoring","RECRUITING","2026-05-05",{"date":46,"type":47},"2026-05-11","ACTUAL",{"date":49,"type":47},"2022-12-21",{"date":51,"type":22},"2032-12-21",{"name":53,"class":54},"University of Galway","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100624565","gut-microbiota-modulation-with-synbiotics-after-acute-coronary-syndrome-100624565","NCT07411287","Gut Microbiota Modulation With Synbiotics After Acute Coronary Syndrome","Gut Microbiota Modulation With Synbiotics as Secondary Prevention After Acute Coronary Syndrome: A Randomized-Controlled Trial Pilot Study","SYMBIO-ACS","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Adult patients capable of providing discernment informed consent\n* Recent (\\\u003C 1 week) diagnosis of acute coronary syndrome as defined in the last 2023 ESC guidelines and the Fourth universal definition of myocardial infarction, including unstable angina or myocardial infarction with or without ST-elevation, managed either with best guideline-directed medical therapy or percutaneous coronary intervention.\n\n  * Myocardial injury: Elevated cardiac troponins (cTn) value above the 99th percentile URL. The injury is considered acute if there is a rise and\u002For fall of cTn values.\n  * Unstable angina: Myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury\u002Fnecrosis. Prolonged (\\>20 min) angina at rest; new onset of severe angina; angina that is increasing in frequency, longer in duration, or lower in threshold; or angina that occurs after a recent episode of MI\n  * Type 1 myocardial infarction: Detection of a rise and\u002For fall of cTn values with at least one value above the 99th percentile URL and with at least one of the following: Symptoms of acute myocardial ischaemia; New ischaemic ECG change; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology;Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy\n* Mastering French or German or capacity to be helped with adequate translation\n\nExclusion Criteria:\n\n* Contraindications to symbiotics as listed in Section 3.5.5, that is: immunocompromised individuals, intensive care patients (or critical state), severe valvulopathiesvalvular heart diseases, endocarditis antecedent, known allergy, chronic intestinal diseases or risk factors for small intestine bacterial overgrowth (SIBO) (severe malabsorption or history of digestive surgery), or severe comorbidities (see under)\n* Severe hepatic or renal dysfunction (defined as eGFR \\\u003C30 mL\u002Fmin\u002F1,73 m², dialysis or Child-Pugh score class C)\n* Limited life expectancy (\\\u003C1 year) or progressive malignant disease\n* Type 2 myocardial infarction: Detection of a rise and\u002For fall of cTn values with at least one value above the 99th percentile URL, and evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute coronary athero-thrombosis, requiring at least one of the following: Symptoms of acute myocardial ischaemia; New ischaemic ECG changes; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology.\n* Ongoing pre\u002Fprobiotic supplementation\n* Chronic antibiotherapy or within less than 3 months\n* Women who are pregnant or breast feeding\n* Intention to become pregnant during the course of the study\n* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases (Female participants who are surgically sterilised \u002F hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential)\n* Known or suspected non-compliance, drug or alcohol abuse, dement patients not living in assisted nurse facility care or without supervised treatment administration\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Previous enrolment into the current study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons",{"count":65,"type":22},80,"INTERVENTIONAL",[68],"NA","Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide despite major advances in acute management and secondary prevention. Gut dysbiosis has been described as linked to cardiovascular events. Modulating the gut microbiota through symbiotics-a combination of probiotics and prebiotics-represents a promising, low-risk and widely accessible strategy to influence these pathways and contribute to the enhancement of cardiovascular prevention, with regards to the global burden as well as health costs.\n\nThe SYMBIO-ACS study is therefore designed to assess the effects of a symbiotic intervention on TMAO levels and identify new cardiometabolic biomarkers in patients following ACS, providing essential pilot data for future larger-scale preventive trials.",[32,71],"Microbiota","NOT_YET_RECRUITING","2026-02-11",{"date":75,"type":47},"2026-02-13",{"date":77,"type":22},"2026-06-01",{"date":79,"type":22},"2028-05-31",{"name":81,"class":54},"Centre Hospitalier de Bienne",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":66,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":55},"100572831","digital-secondary-prevention-after-atherosclerotic-cardiovascular-disease-100572831","NCT06738381","Digital Secondary Prevention After Atherosclerotic Cardiovascular Disease","Individually Tailored Digital Secondary Prevention After Hospitalization for Atherosclerotic Cardiovascular Disease: a Randomized Proof-of-concept Study","Inclusion criteria (all the following):\n\n* Aged \\>=18 years and signed informed consent and expected cooperation according to ICH\u002FGCP and national\u002Flocal regulations\n* Hospitalised with an planned or unplanned ASCVD event and\u002For established atherosclerosis\n* Access to a smartphone or tablet\n\nExclusion criteria (any of the following):\n\n-Any condition or situation, that in the investigator's opinion could put the subject at significant risk, confound the study results, interfere significantly with the subject participation in the study, or rendering informed consent unfeasible not limited to: cognitive impairment, seizure disorders, active suicidal intent or plans, substance or alcohol dependence, psychotic disease, major depressive disorders or bipolar disorders, receiving concurrent psychological treatments, and ongoing night shift work.\n\n* Short life expectancy (\\\u003C12 months) due to end-organ (i.e COPD 4, CKD 4\u002F5) or malignant diseases\n* Clinically significant symptoms of anxiety and depression (HADS A and\u002For HADS-D score ≥8)\n* Not being able to understand Norwegian.",{"count":90,"type":22},300,[68],"Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality worldwide and in Norway. Approximately 50% of the patients admitted to hospitals with an acute ASCVD event has had a previous event. The high number of patients being readmitted to hospitals with new ASCVD events is to a large degree explained by poor control of established risk factors such as high LDL-cholesterol, high blood pressure (BP), diabetes, obesity, smoking, and lack of physical activity, as well as poor adherence to evidence-based medication. This pragmatic, open-label proof-of-concept study conducted at three secondary care hospitals will randomly assign patients hospitalized with an ASCVD event to either: (i) brief advice, tailored discharge information to general practitioners, and a nurse-led outpatient visit (control), or (ii) the same interventions as (i) plus a single in-hospital motivational counselling session and access to a digital platform for a 6 months period with patient information\u002Fvideos and an individualized treatment plan and follow-up plan. The primary end point will be between-group differences in the proportion who report having attended follow-up visits in primary (primary care physicians and community-based healthy life centres) and specialist (cardiac rehabilitation programs, hospital outpatient visits) healthcare after 8 weeks and 6 months follow-up. Secondary end points will be change in the SMART2 risk score and cardiovascular risk factors between baseline and 6 and 12 months follow-up. Exploratory end points will be changes in adherence to cardiovascular drugs, self-care behaviour, health literacy, patient activation, and quality of life.",[32,94,95],"Atheroscleroses, Cerebral","Atherosclerotic Ischemic Disease","2025-02-19",{"date":98,"type":47},"2025-02-21",{"date":100,"type":47},"2025-02-03",{"date":102,"type":22},"2026-12-20",{"name":104,"class":54},"Vestre Viken Hospital Trust",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":18,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":66,"phases":117,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":55},"100561426","phase-2-evaluating-the-impact-of-39tertinat39-on-patients-with-atherosclerosis-related-cardiovascular-diseases-100561426","NCT06590012","Evaluating the Impact of 'Tertinat' on Patients with Atherosclerosis-Related Cardiovascular Diseases","Prospective, Double-blind, Comparative Randomized Placebo-controlled Multicenter Study Evaluating the Impact of Oral Administration of the Peroral Supplement "Tertinat" with Dosage of 330 Mg\u002Fday for Patients with Cardiovascular Diseases, the Cause of Which is Atherosclerosis, on the Background of Standard Treatment.","TERACAD","Inclusion Criteria:\n\n* Patients with cardiovascular disease disease of atherosclerotic origin, requiring hospitalization and treatment hospital conditions. Cardiovascular diseases may include the following nosology: Coronary heart disease; Atherosclerosis. Diseases include (and\u002For) atherosclerotic lesions of the coronary arteries, brachiocephalic arteries, limb arteries, renal arteries requiring surgical revascularization.\n* Patients who have undergone a complex of necessary by current standards for their disease instrumental and laboratory examinations, including ECG, severity assessment vascular stenosis (ultrasound, CT, angiography), including large arteries, brachiocephalic arteries, femoral arteries, biochemical blood test assessing the level of general cholesterol, triglycerides, lipoproteins low density, high lipoprotein density, glucose level.\n* Possibility of monitoring the patient - Possibility every 12 months call the patient for questioning and examination.\n* The patient has signed informed consent.\n\nExclusion Criteria:\n\n* Critical and urgent cardiovascular conditions: tissue ischemia stage III-IV, stroke, acute coronary syndrome, myocardial infarction, chronic heart failure III and IV class NYHA (New York Heart Association).\n* Other critical and urgent conditions not associated with cardiovascular diseases, including the need for urgent interventions, chronic renal failure stages IV-V (creatinine clearance \\\u003C 30 ml \u002F min according to the Cockcroft-Gault Equation)\n* Systemic autoimmune diseases in medical history, including: rheumatoid arthritis, systemic lupus erythematosus, autoimmune thyroiditis, autoimmune vasculitis, ulcerative colitis.\n* Significant weight loss (\\> 10% of body weight in the previous year) of unknown etiology.\n* Conditions that limit adherence to participation in the study (dementia, neuropsychiatric diseases, drug addiction, alcoholism, etc.).\n* Participation in other clinical studies (or use of investigational substances) within 3 months prior to study entry.\n* Carriers of HIV or viral hepatitis\n* Pregnancy or breast feeding\n* Refusal to participate in the study.","45 Years","75 Years",{"count":116,"type":22},556,[118],"PHASE2","The aim of this clinical trial is to evaluate whether the biologically active food supplement, Tertinat, can influence atherosclerosis progression in adults and improve the treatment outcomes of cardiovascular diseases. The study will assess the frequency of fatal and clinically significant cardiovascular events, monitored every 12 months following participants\\' inclusion in the trial.\n\nAdditionally, the trial will evaluate Tertinat's ability to prevent pro-atherogenic modification of lipoproteins and its impact on inflammatory activity. To this end, levels of desialylated low-density lipoproteins (LDL) and inflammatory markers in the blood will be monitored. Tertinat administration will occur alongside the standard therapy prescribed to patients based on their existing medical conditions.\n\nResearchers will compare the effects of the Tertinat supplement to a placebo (an identical-looking substance that does not contain the active supplement) to determine if Tertinat is effective in reducing cardiovascular events .\n\nParticipants will:\n\nTake either Tertinat or a placebo daily for a duration of 24 months. Visit the clinic once a year for check-ups and testing.",[121,32,122],"Atherosclerosis","Carotid Atherosclerosis",[124,125,126,127],"atherosclerosis","lipoproteins","coronary atherosclerosis","carotid atherosclerosis","2024-09-06",{"date":130,"type":47},"2024-09-19",{"date":132,"type":47},"2024-08-29",{"date":134,"type":22},"2026-03-01",{"name":136,"class":54},"Institute for Atherosclerosis Research, Russia",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":18,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":66,"phases":148,"briefSummary":149,"conditions":150,"keywords":153,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":55},"100530123","concurrent-oct-and-ffr-guided-pci-in-cad-100530123","NCT06182683","Concurrent OCT and FFR-guided PCI in CAD","Concurrent OPTIcal Coherence Tomography and frActional Flow REserve-guided Therapeutic Intervention in Patients With Coronary Artery Disease (OPTICARE-CAD)","OPTICARE-CAD","Inclusion Criteria:\n\n1. Age greater than 19 years old\n2. Patients undergoing coronary stent implantation for stable angina or acute coronary syndrome\n3. Patients provided on informed consent\n\nExclusion Criteria:\n\n1. Individuals with a history of increased bleeding tendencies or hematologic disorders\n2. Presented with refractory cardiogenic shock\n3. Individuals with a history of stent thrombosis\n4. Expected life expectancy of less than 1 year\n5. Left ventricular ejection fraction (LVEF) ≥ 20%\n6. Women who are breastfeeding, pregnant, or planning to become pregnant\n7. Deemed unsuitable for participation by the investigator\n8. Patients unwilling to participate in the clinical trial","19 Years",{"count":147,"type":22},700,[68],"The present study is a prospective randomized clinical trial aimed to compare the therapeutic strategy of angiography-guided versus concurrent OCT\u002FFFR-guided intervention in patients with coronary artery disease.",[151,152,32],"Coronary Artery Disease","Image",[154,155,156,157,158,159],"Optical coherence tomography","Fractional flow reserve","Angiography","Coronary artery disease","Percutaneous coronary intervention","Drug-eluting stent","2023-12-25",{"date":162,"type":47},"2023-12-27",{"date":164,"type":47},"2023-11-30",{"date":166,"type":22},"2029-12-31",{"name":168,"class":54},"Korea University Guro Hospital"]